when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Immunology · news · pharmadog

← back to Immunology

News mentioning Immunology

183 stories

Aug 25, 26China’s Haisco forms immunology biotech with up to $1.5B from American VCsbiospace

Aug 25, 26Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failbiospace

Aug 19, 26She grew up unvaccinated. Now she’s a leading voice for science — and empathystat

Aug 18, 26Regeneron ends eye disease study due to antibody's safety profilebiospace

Aug 18, 26Regeneron ends eye disease study due to antibody's safety profilebiospace

Aug 17, 26Biotech's reverse merger renaissance poised to continueendpoints

Aug 17, 26Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidatefiercebiotech

Aug 14, 26‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryfiercebiotech

Aug 13, 26STAT+: Eli Lilly targets booming black market for retatrutidestat

Aug 12, 26Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

Aug 12, 26Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drugendpoints

Aug 12, 26STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapiesstat

Aug 12, 26With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentbiospace

Aug 11, 26CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaquesfiercebiotech

Aug 11, 26Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsfiercebiotech

Aug 11, 26Epicrispr, Infinimmune snag combined $165M in VC cashbiospace

Aug 11, 26Austria’s new growth fund could further bolster its dynamic biotech innovation economybiospace

Aug 6, 26Chutes & Ladders—BioNTech brings in Sobi CEOfiercebiotech

Aug 6, 26Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’biospace

Aug 6, 26Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengruifiercebiotech

Aug 5, 26Novo CEO sees innovation as a matter of survival amid pipeline setbacksbiospace

Aug 5, 26Attovia extends biotech IPO streak with $289M listing for three I&I drugsendpoints

Aug 5, 265 NextGen winners who went public this year (and which ones are hiring)biospace

Aug 5, 264 potential biotech M&A targets, plus a pretty sure bet from J&Jbiospace

Aug 5, 26Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOfiercebiotech

Aug 4, 26Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missbiospace

Aug 3, 26BioNTech taps Sobi executive Oelkers as its next CEObiopharma dive

Aug 3, 26BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechbiospace

Aug 3, 26Novo’s late-stage IL-6 stumble shakes inflammation spacebiospace

Jul 31, 26AbbVie touts strong momentum for Skyrizi despite rising competitionendpoints

← prevpage 4 of 7next →